Black Diamond Therapeutics (NASDAQ:BDTX) Stock Lifted to “Hold” by Wall Street Zen

by · The Markets Daily

Wall Street Zen upgraded shares of Black Diamond Therapeutics (NASDAQ:BDTX – Free Report) from a sell rating to a hold rating in a research note issued to investors on Saturday morning,Wall Street Zen reports.

A number of other equities analysts have also recently weighed in on BDTX. Raymond James Financial restated an “outperform” rating on shares of Black Diamond Therapeutics in a report on Thursday, August 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Black Diamond Therapeutics in a research report on Friday, October 9th. Jefferies Financial Group restated a “buy” rating on shares of Black Diamond Therapeutics in a research note on Thursday, August 6th. Finally, TD Cowen restated a “buy” rating on shares of Black Diamond Therapeutics in a research note on Thursday, August 6th. Seven equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $11.00.

Read Our Latest Research Report on BDTX

Black Diamond Therapeutics Price Performance

Black Diamond Therapeutics stock opened at $1.88 on Friday. The stock’s 50-day moving average is $1.98 and its 200-day moving average is $2.14. The company has a market cap of $108.01 million, a price-to-earnings ratio of -2.51 and a beta of 3.32. Black Diamond Therapeutics has a 12 month low of $1.60 and a 12 month high of $4.94.

Black Diamond Therapeutics (NASDAQ:BDTX – Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.03. Research analysts anticipate that Black Diamond Therapeutics will post -0.57 EPS for the current year.

Institutional Trading of Black Diamond Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Beacon Capital Management LLC lifted its holdings in shares of Black Diamond Therapeutics by 64.0% in the third quarter. Beacon Capital Management LLC now owns 25,615 shares of the company’s stock valued at $48,000 after buying an additional 10,000 shares during the period. Spark Investment Management LLC acquired a new stake in Black Diamond Therapeutics during the 2nd quarter worth about $29,000. RB Capital Management LLC purchased a new position in Black Diamond Therapeutics during the second quarter valued at approximately $185,000. Empowered Funds LLC purchased a new stake in Black Diamond Therapeutics in the 2nd quarter worth approximately $459,000. Finally, Bank of America Corp DE purchased a new stake in shares of Black Diamond Therapeutics during the second quarter worth $765,000. Institutional investors own 95.47% of the company’s stock.

About Black Diamond Therapeutics

(Get Free Report)

Black Diamond Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetically defined cancers. The company uses its proprietary MasterKey platform to identify and develop small-molecule therapies designed to address oncogenic mutations across multiple tumor types, including alterations that may be difficult to target with conventional approaches.

Black Diamond’s pipeline has included brain-penetrant therapies for cancers affecting the central nervous system.

Further Reading